MedTrace Logo

Clinical Trial to Evaluate the Efficacy and Safety of CKD-495 Tablet

NCT03437785 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2018-10-31

No results posted yet for this study

Summary

To Evaluate the Efficacy and Safety of CKD-495

Conditions

  • Gastritis

Interventions

DRUG

CKD-495 75mg

CKD-495 75mg Tab.

DRUG

CKD-495 150mg

CKD-495 150mg Tab.

DRUG

Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg

Artemisiae argyi folium 95% ethanol ext.(20→1) 60mg Tab.

DRUG

Rebamipide 100mg

Rebamipide 100mg Tab.

DRUG

Placebo of the CKD-495 75mg

Placebo of the CKD-495 75mg Tab.

DRUG

Placebo of the CKD-495 150mg

Placebo of the CKD-495 150mg Tab.

DRUG

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg

Placebo of Artemisia Herb 95% Ethanol Soft Ext.(20→1) 60mg Tab.

DRUG

Placebo of the Rebamipide 100mg

Placebo of the Rebamipide 100mg Tab

Sponsors & Collaborators

  • Chong Kun Dang Pharmaceutical

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-16
Primary Completion
2018-10-12
Completion
2018-10-12

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03437785 on ClinicalTrials.gov